MML Investors Services LLC Has $277,000 Position in Twist Bioscience Co. (NASDAQ:TWST)

MML Investors Services LLC decreased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 51.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,124 shares of the company’s stock after selling 6,596 shares during the quarter. MML Investors Services LLC’s holdings in Twist Bioscience were worth $277,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Signaturefd LLC lifted its stake in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience during the second quarter worth approximately $61,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after acquiring an additional 381 shares during the period. Farther Finance Advisors LLC grew its position in shares of Twist Bioscience by 1,173.8% in the third quarter. Farther Finance Advisors LLC now owns 3,401 shares of the company’s stock valued at $154,000 after purchasing an additional 3,134 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in shares of Twist Bioscience by 224.3% during the third quarter. Blue Trust Inc. now owns 3,810 shares of the company’s stock worth $188,000 after purchasing an additional 2,635 shares during the period.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 659 shares of the firm’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $27,388.04. Following the transaction, the insider now directly owns 94,481 shares of the company’s stock, valued at approximately $3,926,630.36. This trade represents a 0.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Paula Green sold 860 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $45,322.00. Following the sale, the senior vice president now directly owns 133,715 shares of the company’s stock, valued at approximately $7,046,780.50. The trade was a 0.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 99,659 shares of company stock valued at $4,484,602. Company insiders own 3.92% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on TWST shares. Scotiabank upped their price objective on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 19th. TD Cowen restated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Twist Bioscience Price Performance

Shares of TWST opened at $48.90 on Thursday. The stock has a 50-day moving average of $45.51 and a 200-day moving average of $46.72. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The company has a market cap of $2.90 billion, a PE ratio of -13.58 and a beta of 1.82.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.